Acute In-Hospital Stress Disorder/Anxiety/Insomnia Medications
For acutely hospitalized adults with stress-related anxiety and insomnia, use low-dose melatonin (3-5 mg) as first-line pharmacotherapy, with trazodone (25-50 mg) as second-line if melatonin fails, while avoiding benzodiazepines and Z-drugs (zolpidem, eszopiclone) due to their significant risks of falls, cognitive impairment, and delirium in the hospital setting.
Medication Selection Algorithm
First-Line: Melatonin
- Start with melatonin 3-5 mg at bedtime 1
- Lowest risk profile with minimal adverse effects and drug-drug interactions
- At least as effective as sedative-hypnotics in the inpatient setting 1
- Particularly appropriate for patients over 65 years old where benzodiazepines are relatively contraindicated 1
Second-Line: Trazodone
- Use trazodone 25-50 mg if melatonin inadequate 2, 3
- Evidence supports use for insomnia secondary to major depressive disorder and anxiety 2
- In head-to-head comparison, 34.6% of trazodone patients needed additional sleep aids versus 19.7% with melatonin (though not statistically significant) 3
- Similar adverse event profile to melatonin in hospitalized patients 3
Third-Line: Consider Context-Specific Agents
- For anxiety-predominant presentations: Eszopiclone or zolpidem may be considered 2, though evidence shows only small absolute effect sizes 4
- For PTSD-related insomnia: Prazosin 2
- For bipolar mania with insomnia: Second-generation antipsychotic 2
Critical Caveats for Hospital Setting
Avoid Benzodiazepines and Z-Drugs When Possible
The inpatient environment creates unique risks that outweigh the modest benefits of these agents:
- Cognitive and behavioral impairment: FDA documents report risks for driving impairment and behavioral changes 4
- Serious harms from observational data: Increased risk for dementia, fractures, and major injury 4
- Falls and delirium risk: Particularly problematic in hospitalized older adults 1
- Hospital systems are actively moving away: Recent quality improvement efforts show success in reducing benzodiazepine receptor agonist prescriptions in inpatient settings 5
Evidence Strength Considerations
The American College of Physicians guideline 4 found only low-to-moderate strength evidence for eszopiclone, zolpidem, and suvorexant with small absolute effect sizes. This modest benefit does not justify the substantial risks in acutely ill hospitalized patients where fall risk, delirium risk, and polypharmacy concerns are heightened.
Practical Implementation
Dosing specifics:
- Melatonin: 3-5 mg administered 30-60 minutes before desired sleep time
- Trazodone: Start 25-50 mg at bedtime; can titrate to 100 mg if needed
- If Z-drugs absolutely necessary: Use lowest effective dose, particularly reduced doses in women and older adults per FDA guidance 4
Duration:
- Target short-term use only in hospital
- Reassess daily whether continued pharmacotherapy needed
- Address underlying stressors, pain, environmental factors concurrently
Special populations:
- Older adults (≥65 years): Strongly favor melatonin over benzodiazepines/Z-drugs 1
- Patients with psychiatric comorbidity: Match agent to primary disorder (e.g., trazodone for depression, prazosin for PTSD) 2
- Avoid polypharmacy: Do not start multiple sleep aids simultaneously 3
What NOT to Do
- Do not reflexively prescribe benzodiazepines despite their common use (55.9-69.6% in some settings) 6 - this represents poor adherence to evidence
- Do not continue hospital-initiated hypnotics at discharge without clear indication - 39-46% continuation rates suggest inappropriate chronic use 3
- Do not ignore non-pharmacologic interventions - though not the focus here, sleep hygiene modifications reduce medication needs
The evidence clearly demonstrates that while eszopiclone and zolpidem have FDA approval and modest efficacy data 4, their risk-benefit ratio in the acute hospital setting favors safer alternatives like melatonin and trazodone, which have comparable or superior safety profiles with reasonable efficacy 3, 1.